glp 1 agonist function Glucagon-like peptide-1 A Comprehensive Review of the

Diabetes 2023, 73, 3850

Initially designed for controlling blood sugar levels, medications like Ozempic (semaglutide), and Mounjaro (tirzepatide) have proven to deliver impressive weight-loss results, leading to their swift acceptance beyond diabetes treatment

Patients with T2DM and obesity exhibit an elevated risk of adverse cardiovascular events

The action of GLP-1 and GIP on the pancreas causes a reduction in glucagon secretion that results in diminished hepatic glucose production

Subsequent studies revealed that co-infusion of GLP-1 with GCG can mitigate the GCG-induced hyperglycaemia [34], while preserving GCGs metabolic benefits, providing a strong rationale for the development of GLP1/GCG co-agonists as obesity treatments (Fig

Secreted GLP-1 then impedes gastrointestinal motility at the level of myenteric neurons by inhibiting downstream signaling of nitric oxide and cyclic adenosine monophosphate (cAMP) dependent pathways that inhibit vagal activity [10]